Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | CES2 | O00748 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.69 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | RECQL | P46063 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | BLM | P54132 | 3/20 | 0.69 |
| ▸ | CES1 | P23141 | 3/20 | 0.69 |
| ▸ | IDO1 | P14902 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.69 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cryptotanshinone SCHEMBL5940386 | 0.81 | MEN1 (1.00) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| Cryptotanshinone SCHEMBL29387944 | 0.81 | MEN1 (1.00) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| Cryptotanshinone SCHEMBL4126834 | 0.81 | MEN1 (1.00) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL3332927 | 0.81 | PTPN1 (0.69) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL13855041 | 0.80 | PTPN1 (0.64) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL3329728 | 0.80 | PTPN1 (0.64) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL3328952 | 0.79 | MEN1 (0.62) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL20671274 | 0.77 | PTPN1 (0.62) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL13883845 | 0.76 | MEN1 (0.74) | PTPN1MEN1ALDH1A1KMT2ACES2 | |
| SCHEMBL16298225 | 0.75 | PTPN1 (0.57) | PTPN1MEN1ALDH1A1KMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | EMORY UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | PTPN1 1331/4885MEN1 1932/4885ALDH1A1 4131/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | PTPN1 2577/4885MEN1 3639/4885ALDH1A1 1929/4885 |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | ACE2, SARS1, VIP | PTPN1 1331/4885MEN1 1932/4885ALDH1A1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.